FDA approves first generic Strattera for the treatment of ADHD

 
u s food and drug administration

News Release

Bookmark and Share

 

05/30/2017 04:49 PM EDT

The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

###


This email was sent to Email Address using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) Powered by GovDelivery

This email was sent to bsamad2007.adnan@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) Powered by GovDelivery

Comments

Popular Posts

January 3nd Nоte (Оpen Up)

Reduced Payment!.

We have Your e-Wallet ready. Claim in 3hrs

Your order requires immediate confirmation.

Beneficiary countersignature modification

You’re four weeks away from more followers 📱

The State Department requires proof that you are the owner.

Commissions Successfully

Fwd: Claim "Climate law & governance" for your profile